Impact of Iron Deficiency on Response to and Remodeling After Cardiac Resynchronization Therapy

American Journal of Cardiology

Volumn 119, Issue 1, 2017, Pages 65-70

  Martens, Pieter ^a,b   Verbrugge, Frederik ^a   Nijst, Petra ^a,b   Dupont, Matthias ^a   Tang, W H Wilson ^c   Mullens, Wilfried ^a,b  

^a DEPARTMENT OF CARDIOLOGY   (Belgium)

^b HASSELT UNIVERSITY   (Belgium)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRON; BIOLOGICAL MARKER;

AGED; ARTICLE; BLOOD CELL COUNT; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR MORTALITY; CLINICAL OUTCOME; CONTROLLED STUDY; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; IRON DEFICIENCY; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; QRS INTERVAL; RETROSPECTIVE STUDY; TERTIARY CARE CENTER; BELGIUM; BLOOD; DEFICIENCY; DIAGNOSTIC IMAGING; ECHOCARDIOGRAPHY; HEART FAILURE; HEART VENTRICLE REMODELING; TREATMENT OUTCOME;

AGED; BELGIUM; BIOMARKERS; CARDIAC RESYNCHRONIZATION THERAPY; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HUMANS; IRON; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 85001874935     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2016.09.017     Document Type: Article

References (30)

1. 1 Anand, I.S., Kuskowski, M.A., Rector, T.S., Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation 112 (2005), 1121–1127.
2. 2 Mullens, W., Grimm, R.A., Verga, T., Insights from a cardiac resynchronization optimization clinic as part of a heart failure disease management program. J Am Coll Cardiol 53 (2009), 765–773.
3. 3 Venkateswaran, R.V., Freeman, C., Chatterjee, N., Anemia and its association with clinical outcome in heart failure patients undergoing cardiac resynchronization therapy. J Interv Card Electrophysiol 44 (2015), 297–304.
4. 4 Kazory, A., Ross, E.A., Anemia: the point of convergence or divergence for kidney disease and heart failure?. J Am Coll Cardiol 53 (2009), 639–647.
5. 5 Rickard, J., Kumbhani, D.J., Gorodeski, E.Z., Elevated red cell distribution width is associated with impaired reverse ventricular remodeling and increased mortality in patients undergoing cardiac resynchronization therapy. Congest Heart Fail 18 (2012), 79–84.
6. 6 Jankowska, E.A., Rozentryt, P., Witkowska, A., Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 31 (2010), 1872–1880.
7. 7 Anker, S.D., Comin, C.J., Filippatos, G., Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361 (2009), 2436–2448.
8. 8 Ponikowski, P., van Veldhuisen, D.J., Comin-Colet, J., Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiencydagger. Eur Heart J 36 (2015), 657–668.
9. 9 Dong, F., Zhang, X., Culver, B., Chew, H.G. Jr., Kelley, R.O., Ren, J., Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrome c release: involvement of nitric oxide synthase and protein tyrosine nitration. Clin Sci (Lond) 109 (2005), 277–286.
10. 10 Naito, Y., Tsujino, T., Matsumoto, M., Sakoda, T., Ohyanagi, M., Masuyama, T., Adaptive response of the heart to long-term anemia induced by iron deficiency. Am J Physiol Heart Circ Physiol 296 (2009), H585–H593.
11. 11 Turner, L.R., Premo, D.A., Gibbs, B.J., Adaptations to iron deficiency: cardiac functional responsiveness to norepinephrine, arterial remodeling, and the effect of beta-blockade on cardiac hypertrophy. BMC Physiol, 2, 2002, 1.
12. 12 McMurray, J.J., Adamopoulos, S., Anker, S.D., Esc guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 14 (2012), 803–869.
13. 13 Mullens, W., Kepa, J., De, V.P., Importance of adjunctive heart failure optimization immediately after implantation to improve long-term outcomes with cardiac resynchronization therapy. Am J Cardiol 108 (2011), 409–415.
14. 14 Okonko, D.O., Grzeslo, A., Witkowski, T., Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 51 (2008), 103–112.
15. 15 Schiller, N.B., Shah, P.M., Crawford, M., Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2 (1989), 358–367.
16. 16 Jankowska, E.A., von, H.S., Anker, S.D., Macdougall, I.C., Ponikowski, P., Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J 34 (2013), 816–829.
17. 17 Verbrugge, F.H., Dupont, M., Rivero-Ayerza, M., Comorbidity significantly affects clinical outcome after cardiac resynchronization therapy regardless of ventricular remodeling. J Card Fail 18 (2012), 845–853.
18. 18 Melman, Y.F., Shah, R., Danielson, K., Circulating MicroRNA-30d is associated with response to cardiac resynchronization therapy in heart failure and regulates cardiomyocyte apoptosis: a translational pilot study. Circulation 131 (2015), 2202–2216.
19. 19 Munzel, T., Gori, T., Keaney, J.F. Jr., Maack, C., Daiber, A., Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications. Eur Heart J 36 (2015), 2555–2564.
20. 20 DeMazumder, D., Kass, D.A., O'Rourke, B., Tomaselli, G.F., Cardiac resynchronization therapy restores sympathovagal balance in the failing heart by differential remodeling of cholinergic signaling. Circ Res 116 (2015), 1691–1699.
21. 21 Lichter, J.G., Carruth, E., Mitchell, C., Remodeling of the sarcomeric cytoskeleton in cardiac ventricular myocytes during heart failure and after cardiac resynchronization therapy. J Mol Cell Cardiol 72 (2014), 186–195.
22. 22 Kirk, J.A., Holewinski, R.J., Kooij, V., Cardiac resynchronization sensitizes the sarcomere to calcium by reactivating GSK-3beta. J Clin Invest 124 (2014), 129–138.
23. 23 Aiba, T., Barth, A.S., Hesketh, G.G., Cardiac resynchronization therapy improves altered Na channel gating in canine model of dyssynchronous heart failure. Circ Arrhythm Electrophysiol 6 (2013), 546–554.
24. 24 Chakir, K., Depry, C., Dimaano, V.L., Galphas-biased beta2-adrenergic receptor signaling from restoring synchronous contraction in the failing heart. Sci Transl Med, 3, 2011, 100ra88.
25. 25 Wang, S.B., Foster, D.B., Rucker, J., O'Rourke, B., Kass, D.A., Van Eyk, J.E., Redox regulation of mitochondrial ATP synthase: implications for cardiac resynchronization therapy. Circ Res 109 (2011), 750–757.
26. 26 Agnetti, G., Kaludercic, N., Kane, L.A., Modulation of mitochondrial proteome and improved mitochondrial function by biventricular pacing of dyssynchronous failing hearts. Circ Cardiovasc Genet 3 (2010), 78–87.
27. 27 Vanderheyden, M., Mullens, W., Delrue, L., Myocardial gene expression in heart failure patients treated with cardiac resynchronization therapy responders versus nonresponders. J Am Coll Cardiol 51 (2008), 129–136.
28. 28 Usmanov, R.I., Zueva, E.B., Silverberg, D.S., Shaked, M., Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J Nephrol 21 (2008), 236–242.
29. 29 Toblli, J.E., Lombrana, A., Duarte, P., Di, G.F., Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 50 (2007), 1657–1665.
30. 30 Jankowska, E.A., Rozentryt, P., Witkowska, A., Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. J Card Fail 17 (2011), 899–906.